Shanghai Pharmaceuticals (601607.SH) Gains Approval for Minoxidil Tincture Production

Stock News

Dec 05

Shanghai Pharmaceuticals Holding Co., Ltd. (601607.SH) announced that its subsidiary, SPD Jiangsu Pharmaceutical Co., Ltd., has received the Drug Registration Certificate (No. 2025S03530, 2025S03531) from China's National Medical Products Administration (NMPA) for the production approval of Minoxidil Tincture.

Originally developed by Johnson & Johnson, the 2% formulation of Minoxidil Tincture was first launched in the U.S. in 1988, followed by the 5% formulation in 1997. The 2% concentration is indicated for treating male pattern baldness and alopecia areata, while the 5% version is exclusively for male use in addressing the same conditions.

SPD Jiangsu submitted the registration application for this product to the NMPA in January 2024, which was subsequently accepted. As of the announcement date, the company has invested approximately RMB 6.56 million in R&D for this drug.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1152073650"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1152073650\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1152073650?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-05 16:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1152073650","market":"us","top_or_hot":-1,"title":"Shanghai Pharmaceuticals (601607.SH) Gains Approval for Minoxidil Tincture Production","media":"Stock News","content":"<p>Shanghai Pharmaceuticals Holding Co., Ltd. (601607.SH) announced that its subsidiary, SPD Jiangsu Pharmaceutical Co., Ltd., has received the Drug Registration Certificate (No. 2025S03530, 2025S03531) from China's National Medical Products Administration (NMPA) for the production approval of Minoxidil Tincture.</p>\n<p>Originally developed by Johnson & Johnson, the 2% formulation of Minoxidil Tincture was first launched in the U.S. in 1988, followed by the 5% formulation in 1997. The 2% concentration is indicated for treating male pattern baldness and alopecia areata, while the 5% version is exclusively for male use in addressing the same conditions.</p>\n<p>SPD Jiangsu submitted the registration application for this product to the NMPA in January 2024, which was subsequently accepted. As of the announcement date, the company has invested approximately RMB 6.56 million in R&D for this drug.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shanghai Pharmaceuticals (601607.SH) Gains Approval for Minoxidil Tincture Production</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShanghai Pharmaceuticals (601607.SH) Gains Approval for Minoxidil Tincture Production\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-12-05 16:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shanghai Pharmaceuticals Holding Co., Ltd. (601607.SH) announced that its subsidiary, SPD Jiangsu Pharmaceutical Co., Ltd., has received the Drug Registration Certificate (No. 2025S03530, 2025S03531) from China's National Medical Products Administration (NMPA) for the production approval of Minoxidil Tincture.</p>\n<p>Originally developed by Johnson & Johnson, the 2% formulation of Minoxidil Tincture was first launched in the U.S. in 1988, followed by the 5% formulation in 1997. The 2% concentration is indicated for treating male pattern baldness and alopecia areata, while the 5% version is exclusively for male use in addressing the same conditions.</p>\n<p>SPD Jiangsu submitted the registration application for this product to the NMPA in January 2024, which was subsequently accepted. As of the announcement date, the company has invested approximately RMB 6.56 million in R&D for this drug.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02607","symbol_name":"上海医药","start_time":0,"source_url":"","article_id":"1152073650","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1152073650","pubTimestamp":1764922231,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Shanghai Pharmaceuticals Holding Co., Ltd. (601607.SH) announced that its subsidiary, SPD Jiangsu Pharmaceutical Co., Ltd., has received the Drug Registration Certificate (No. 2025S03530, 2025S03531)...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"601607":"上海医药","02607":"上海医药","BK0184":"上海国资改革","BK0099":"上海本地重组","BK0028":"国家队","BK0187":"一线龙头","BK0097":"医药电商","BK0020":"浦东新区","BK1197":"保健护理产品经销商","BK0209":"零售","BK0183":"MSCI概念","BK0188":"融资融券","BK0196":"行业龙头","BK0012":"证金概念","BK0175":"白马股"},"translate_title":"上海医药（601607.SH）米诺地尔酊剂生产获批","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"601607":1,"02607":1},"content_text":"Shanghai Pharmaceuticals Holding Co., Ltd. (601607.SH) announced that its subsidiary, SPD Jiangsu Pharmaceutical Co., Ltd., has received the Drug Registration Certificate (No. 2025S03530, 2025S03531) from China's National Medical Products Administration (NMPA) for the production approval of Minoxidil Tincture.\nOriginally developed by Johnson & Johnson, the 2% formulation of Minoxidil Tincture was first launched in the U.S. in 1988, followed by the 5% formulation in 1997. The 2% concentration is indicated for treating male pattern baldness and alopecia areata, while the 5% version is exclusively for male use in addressing the same conditions.\nSPD Jiangsu submitted the registration application for this product to the NMPA in January 2024, which was subsequently accepted. As of the announcement date, the company has invested approximately RMB 6.56 million in R&D for this drug.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}